Welcome to our dedicated page for Ra Medical Systems news (Ticker: RMED), a resource for investors and traders seeking the latest updates and insights on Ra Medical Systems stock.
Ra Medical Systems, Inc. (NYSE: RMED) is a pioneering developer of excimer laser technologies for vascular and dermatological treatments, now expanding into cardiac electrophysiology solutions. This news hub provides investors and healthcare professionals with timely updates on regulatory milestones, clinical advancements, and strategic initiatives shaping the company's transition to Catheter Precision, Inc.
Access comprehensive coverage of RMED's innovative medical devices including the VIVO™ imaging system and DABRA catheter technology. Track developments in international expansion efforts and key partnerships driving adoption of minimally invasive therapies. Our curated news collection ensures you stay informed about FDA clearances, European regulatory progress, and evolving treatment applications.
Find updates on:
• New product approvals and clinical trial results
• Strategic partnerships with medical distributors
• Regulatory filings including CE Mark applications
• Hospital adoption metrics for vascular therapies
• Corporate restructuring and leadership changes
Bookmark this page for verified updates on RMED's transition to cardiac-focused innovation. Check regularly for objective reporting on technological breakthroughs impacting both patient care and long-term shareholder value.
Ra Medical Systems (NYSE American:RMED) announced the resignation of CEO Will McGuire, effective April 28, 2023, for personal reasons. He will also step down from the board of directors. The board has established a committee to search for a new CEO while Executive Chairman David Jenkins will serve as Interim CEO. The company is focused on developing innovative solutions for cardiac arrhythmias through its subsidiary Catheter Precision. The press release includes a cautionary note regarding forward-looking statements, highlighting potential risks related to executive recruitment and market conditions. Investors are advised to review the company's Annual Report for more insights.
Ra Medical Systems (NYSE American:RMED) announced that its subsidiary, Catheter Precision, is participating in the European Heart Rhythm Association (EHRA) congress in Barcelona from April 16-18, 2023. This event features more than 4,100 members from the cardiology field and focuses on improving treatment for cardiac arrhythmias.
CEO David Jenkins highlighted the significance of the VIVO system, indicating its role in aiding ventricular ablations. Multiple abstracts showcasing VIVO were accepted for presentation at the conference, addressing key advancements in non-invasive electrophysiology and novel imaging techniques.
The VIVO system, which has received both FDA marketing clearance and CE mark, streamlines workflows in electrophysiology procedures by non-invasively identifying arrhythmia origins.
Ra Medical Systems (NYSE American: RMED) announced the appointment of Steven Passey as its new Chief Financial Officer, effective April 1, 2023. This follows the interim role of Brian Conn. Passey brings extensive experience from publicly traded companies and is expected to enhance financial strategy and M&A capabilities as the company prepares for the market launch of its VIVO product line and the LockeT suture retention device. Previous roles include CFO at QSI Holdings and TechniScan. The announcement was made by Executive Chairman David Jenkins, who thanked Conn for his leadership during the merger with Catheter.
Ra Medical Systems, Inc. (NYSE American: RMED) announced the closure of a private placement, generating $8 million in gross proceeds. Executive Chairman David Jenkins highlighted that this capital provides sufficient operating funds through the end of 2024 and supports launching their VIVO product line and LockeT devices. The placement involved issuing 497,908 shares of common stock and 7,203 convertible preferred shares, among other securities. The Company plans to file a registration statement with the SEC to cover the resale of shares. Both VIVO and LockeT aim to enhance cardiac procedure efficiency and outcomes.
Ra Medical Systems (NYSE American:RMED) has successfully secured approval from stockholders for all proposals during a Special Meeting held on March 21, 2023. This includes a planned $8 million financing based on 90% of the 5-day volume weighted average share price, aiming to enhance capital for product development and marketing. Key proposals approved include the issuance of over 19.99% of outstanding common stock through various warrants and the appointment of Haskell & White LLP as the accounting firm for fiscal year 2022. The company emphasizes its growth strategy in innovative cardiac solutions, while also issuing a caution regarding forward-looking statements.
